试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-09-09
Study to Compare Pharmacokinetic Characteristics of Eperisone and Aceclofenac With NVP-1203
编号:NCT02289274登记状态:入组前撤回企业 / 申办者:NVP Healthcare
药物 / 成分:NVP-1203、Eperisone SR tab. + and Airtal tab.
登记的停止原因(原文):internal decision
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-09-09
Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung
编号:NCT02466568登记状态:入组前撤回企业 / 申办者:H. Lee Moffitt Cancer Center and Research Institute
药物 / 成分:Nivolumab、GM.CD40L Vaccine
登记的停止原因(原文):Funding unavailable
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-09-09
Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors
编号:NCT02689336登记状态:入组前撤回企业 / 申办者:Washington University School of Medicine
药物 / 成分:Erlotinib、Temozolomide
登记的停止原因(原文):Could not recruit any participants
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-09-09
Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan
编号:NCT02747537登记状态:入组前撤回企业 / 申办者:Washington University School of Medicine
药物 / 成分:Sorafenib、Irinotecan
登记的停止原因(原文):Could not recruit participants for the study
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-09-09
Comparison of Vaginal and Intramuscular Progesterone in Vitrified-warmed Blastocyst Transfer Cycles
编号:NCT02772120登记状态:入组前撤回企业 / 申办者:Brigham and Women's Hospital
药物 / 成分:Vaginal progesterone gel (Crinone® 8%)、Intramuscular Progesterone
登记的停止原因(原文):Before enrollment, suspended due to changing insurance coverage of study drugs.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-09-06
Progesterone and Atomoxetine for Cocaine Cessation
编号:NCT01741376登记状态:入组前撤回企业 / 申办者:University of Minnesota
药物 / 成分:Progesterone、Placebo
登记的停止原因(原文):All clinical trials within the Department of Psychiatry at UMN were suspended and this study was withdrawn due to no enrollment.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-09-06
A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer
编号:NCT03988114登记状态:入组前撤回企业 / 申办者:Eli Lilly and Company
药物 / 成分:Abemaciclib、Nonsteroidal Aromatase Inhibitor (NSAI)
登记的停止原因(原文):Strategic decision due to emerging new data for patients with HR+, HER2- metastatic breast cancer.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-09-04
Study to Assess Safety and Efficacy of Kabiven® in Pediatric Patients 2 to 16 Years of Age
编号:NCT03481894登记状态:入组前撤回企业 / 申办者:Fresenius Kabi
药物 / 成分:Kabiven®、Compounded standard parenteral nutrition
登记的停止原因(原文):FDA released Fresenius Kabi from this post marketing requirement on 07/16/2019.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-09-03
A Study to Decrease Suicidal Thinking Using Ketamine
编号:NCT02418702登记状态:入组前撤回企业 / 申办者:United States Naval Medical Center, San Diego
药物 / 成分:0.2 mg/kg ketamine、placebo
登记的停止原因(原文):PI no longer at facility.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-08-30
Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion
编号:NCT02053545登记状态:入组前撤回企业 / 申办者:Ann & Robert H Lurie Children's Hospital of Chicago
药物 / 成分:Conditioning Regimen & GVHD Prophylaxis
登记的停止原因(原文):Study closed with no enrollment.
查看官方原始记录 ↗